HHSE BLOG: THE BIG SHORT > THE BIG SQUEEZE... HHSE

New Post Public Reply Private Reply Replies (0) Message Board
speckulater
334
HHSE BLOG: THE BIG SHORT > THE BIG SQUEEZE...




HHSE INVESTOR RELATIONS




Thursday, February 25, 2021


THE BIG SHORT > THE BIG SQUEEZE... AND A RIGHTEOUS VICTORY OVER STOCK MANIPULATORS


Greetings HHSE Friends & Followers - For years now, HHSE has been a proven cash-cow for short-sellers and those engaged in “boxing” the bid-ask spread with trade strategies and computer algorithms. This has been fertile grounds for those near (or past) the line of stock trading legalities... as their strategy only collapses if the buying pressure for HHSE significantly increases, or if the spread is minimized when the PPS is over $.02 / share.



About two weeks ago, HHSE stock began to experience a 10-fold increase in daily volume and a PPS improvement of more than 80%. This new interest in HHSE is being fueled by a myriad of market and “real-world” factors, including excitement for the company's new filings and the launch of the MyFlix multi-studio platform (at a moment when streaming services are a consumer rage).



Unfortunately, as is often the case in the market, when some shareholders flourish, others may flounder... and the recent buying volume of 45-mm shares in a short time frame proved that the "box strategy" to suppress HHSE can be defeated.



This is somewhat reminiscent of what has occurred recently with GAMESTOP and AMC Entertainment - two stocks where the naysayers and manipulators had previously flourished by spreading a foundation of falsehoods and "sky is falling" predictions while short-selling the equity. Fortunately, this "Big Lie" was seen in its truth as a being a "Big Short" (see charts below) - and a cavalry of independent traders turned it into the "Big Squeeze." Short sellers were forced to cover their negative bets, and indie traders made billions as a result.








Now, HHSE is facing new pressure from these professional naysayers. No, it's not any pressure from the obvious falsehoods of the "sky is falling" by trying to equate the personal financial reorganization of one of the officers as being somehow impactful or the same for the company (see further information below).

No, the short-sellers have gotten more desperate than simply using their tired misinformation campaign. The short-sellers are in a panic to protect their bet - which Sage investors have told HHSE that they calculate the total short position to be in excess of ONE-HUNDRED-MILLION (100,000,000) HHSE shares. The recent PPS improvement and buying volume for HHSE proves that the short-sellers could be easily squeezed and forced to cover at $.05 or higher. So, they are having to step-up their game. But if success is the best revenge, a suggested new effort by HHSE LONGS and new buyers to squeeze the naysayers into covering HHSE at a premium seems like a great way to start this year.

HHSE is now informed that absurd misinformation has been fed to E-Trade and TD Ameritrade against HHSE, as a move to suppress the accessibility to new buyers for the stock. A formal complaint has already been filed with E-Trade, and a new complaint will be posted today with TD Ameritrade - as HHSE has received a full bill-of-health from the Securities and Exchange Commission to show that no "real world" rationale exists for these trading platforms to put forward obstacles to ON-LINE buying (HHSE). Essentially, both trading platforms are currently requiring that ON-LINE buyers for HHSE "call in to place an order with a broker" as opposed to the simpler / faster method of electronic self-service. The net effect is to stifle buying, while encouraging selling... an obvious advantage to the short-sellers.

If these arbitrary buying hindrances against HHSE are not promptly removed by E-Trade and TD Ameritrade, HHSE will also use its extensive D.C. political connections to seek Congressional and D.O.J. assistance.

In the meantime... it's clear that we have the short sellers running scared. It's clear that their goal is to HOPE to persuade exhausted longs into selling to them cheap (to cover the short position). And it's clear that solidarity of buyers can beat them at their game... after all, even GAMESTOP is surging yet again on the strength-in-numbers momentum!

As a sage trader once said at one of the HHSE shareholders meetings: Stay Long, Stay Strong! HHSE will prevail!

* * * * *

As mentioned above, some shareholders have asked HHSE why the "creditors list" for the Fred Shefte personal bankruptcy lists a large number of parties who are not now - and in many cases have never been - HHSE creditors. In speaking with Shefte's personal bankruptcy counsel, he was advised to list ANY parties that he thought could, in theory, eventually choose to file a lawsuit claim against Shefte. Rather than limit the list to actual debts or to parties for which Shefte holds a direct obligation, they instead went back to list items over 14-years old, including fully resolved disputes and parties for which no dispute ever existed. It's an absurdly over-reaching list which does not even acknowledge the 4-year statute of limitations in reaching back in time - and instead lists pretty much anyone Fred Shefte ever spoke with relating to a Hannover House project.

Now, what is the "real world" impact of Shefte's personal bankruptcy for those actual and current disputes? For HHSE it's a non-issue, excepting for the potentially positive impact of the "one-judgment rule" which may provide a basis for HHSE to be dismissed in some matters. So when the professional naysayers try (YET AGAIN!) to say that the "sky is falling" (their laughable, ten-year go-to bash), it's just more nonsense designed to try to discourage the one-thing that will KILL their position: buying pressure.


As for the Fred Shefte owned officer-affiliate shares of HHSE, a simple review of the rules, laws and regulations governing the sale restrictions for 144 shares will show that these shares cannot be liquidated in a bankruptcy. There is a mountain of S.E.C. rulings and court precedents to show that officer-owned shares - which are by law restricted from sale - cannot be sold, pledged, assigned, hypothecated or in any way transferred outside of the limitations of Rule 144 of the Securities and Exchange Act of 1933. The professional naysayers suggesting that Shefte's shares will be sold under the bankruptcy are trying to imply that his 17-million shares will be flooding into the open, consumer market. This is not the case and it would not be legal under Federal Securities Laws. If it were legal, public company officers would print themselves billions of shares of stock and use it as currency to pay personal debts. It's just another absurd lie from a stock manipulator to suggest otherwise.


Don't buy into more of their "Big Lies" to cover their "Big Short." Those professional naysayers need to be chased away...



ONWARD!



http://hannoverhousemovies.blogspot.com/2021/...teous.html






Myflix-Image.jpg



Hannover House Inc. (HHSE) Stock Research Links

HHSE Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Savvas Launches Miller & Levine Biology Program Revamp

Updated Category News Views 35

Education Meets Innovation: Savvas Takes a Bold Step Who would have thought biology education could get a makeover that might actually stick? Savvas Learning Company thinks it's onto something with the launch of the all-new Miller & Levine Experience Biology Program. The spotlight's on innovation—it's about time someone shook up the way high schoolers learn biology. A...

Continue Reading
Factory-Built Homes Take Center Stage in New Doc Short

Updated Category News Views 88

Housing is one of those things we all think we understand until we start peeling back the layers of its history, especially when factory-built homes are involved. Here's a new angle: Clayton has just released the teaser for their documentary short, "Built: A Story of Factory-Built Housing in America," and it's turning the lights on a sector that's often left in the...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Unicycive Faces Legal Heat: Shareholder Lawsuit Looms

Updated Category News Views 104

The Unicycive Landslide: What Went Down? Investors, buckle up. Unicycive Therapeutics Inc. (NASDAQ: UNCY) finds itself deep in the muck of a securities class action. Chief honchos, CEO Shalabh Gupta and CFO John Townsend, are taking the heat for allegedly controlling company disclosures that led shareholders to believe in non-existent progress with their third-party...

Continue Reading
SoftwareOne Triumphs in 2026 GitHub Partner Awards

Updated Category News Views 43

SoftwareOne Nabs Prestigious GitHub Honor Outta nowhere, SoftwareOne's been lashed onto the center stage, bagging GitHub's Global Channel Sales Partner of the Year for 2026. This ain't just another shiny trophy on the shelf; it's a solid nod to their grit and strategy. Now, if good old GitHub says you're their top dog, you're obviously doing something right. Not bad for a...

Continue Reading
Data Centers Drive Surge in Power and Cooling Demand

Updated Category News Views 23

Data Centers: The Unseen Powerhouses Don't let the tech jargon fool you—data centers are more than just server rooms. They're beastly energy guzzlers, and their demand is rippling through the supply chain in a big way. You've got companies like Vertiv, American Tower, Johnson Controls, and Generac riding high on this trend, making some serious waves in their quarterly...

Continue Reading
Data Breach at Lumara Bio: Privacy Lawsuits Loom

Updated Category News Views 28

Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....

Continue Reading
Jacobi's Harness Brings AI from Concept to Reality

Updated Category News Views 160

The Challenge of Moving AI to Production Diving headfirst into AI in finance? Well, Jacobi's bold move with their new toy, the Investment Management Harness, spotlights a filthy secret: the hurdles between a big idea and execution are seldom technological. We got AI shaving prototyping time down to just days, yet pushing to production? That's a marathon in itself. Boards...

Continue Reading
Air Canada-CAE Scholarship Drives Women in Aviation

Updated Category News Views 88

A New Chapter for Women in Aviation Call it paving the skies or busting the glass cockpit ceiling, but Air Canada and CAE are really doubling down on getting more women into aviation. They're rolling out the eighth annual Captain Judy Cameron Scholarship, set to open applications on November 1, 2026. With up to eight scholarships on the table for Canadian women eyeing...

Continue Reading
H.R. 10549: Hope Charities Pushes for Pharmacy Freedom

Updated Category News Views 63

Hope Charities Takes a Stand for Patients In Prairieville, Hope Charities is throwing its weight behind a bill they believe is brewing up a patient revolution. The Patients Choice in Specialty Pharmacy Act, otherwise known as H.R. 10549, sparked by Representatives Neal Dunn and Joe Wilson, tackles the comfortable partnerships some insurers have been enjoying with their...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Assistant by ClickBid Revolutionizes Fundraising

Updated Category News Views 155

ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...

Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars

Updated Category News Views 25

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference

Updated Category News Views 147

Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...

Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge

Updated Category News Views 128

Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...

Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone

Updated Category News Views 260

MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...

Continue Reading